medigraphic.com
Academia Mexicana de Neurología, A.C.

2010, Number 1

<< Back Next >>

Rev Mex Neuroci 2010; 11 (1)

Clinical Epidemiology of the Epilepsy

García PF, Millán R, Peñaloza Y

Language: Spanish
References: 47
Page: 82-102
PDF size: 123.92 Kb.


ABSTRACT

Clinical Epidemiology of the Epilepsy (CEE) is a very useful tool for the physician, since its application in patients’ care lets offer an integral medical attention, in which the sick person is considered socioecological context in its and not only as one more case of the suffering. The objective of the present study is to revise some principles and applications of the CEE in the clinical practice to attend patients with epilepsy, as well as to look for its practical definition, its parallelism with the scientific and clinical method, the epidemiological surveillance, risk factor search, development of new treatments, clinical studies, among other aspects.


REFERENCES

  1. Schoenberg BS. General considerations. Advances in Neurology 19. New York: Raven Press; 1978, p. 11-67.

  2. Kwan P, Brodie MJ. Clinical trial of antiepileptic medications in newly diagnosed patients. Neurology 2003; 60 (Suppl 4): S2-12.

  3. Beneson AS. Polimielitis aguda. Manual para el Control de las Enfermedades Trasmisibles. OMS/OPS; 1997: 374-81.

  4. Oficina Panamericana de la Salud. Programa ampliado de inmunizaciones de las Américas. Boletín informativo PAI, OPS/OMS. Washington DC; 2000, p. 1-8.

  5. Miettinen OS. Elements of data analysis and inference. In: Theoretical Epidemiology. Ed. John Wiley and Sons; 1985, 9: 107-9.

  6. Russell N, De Jong Armin FH. Case taking and the neurological examination. Baker’s Clinical Neurology CD-Rom; 2000.

  7. McMahon B, Pugh TF. La estrategia de la epidemiología: Principios y métodos de epidemiología. La Prensa Médica Mexicana 1981, p. 26-42.

  8. Commission on classification and terminology of the international league against epilepsy: Proposal for the classification of epilepsy and epileptic syndromes. Epilepsia 1989: 30: 389-99.

  9. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force of Classification and Terminology. Epilepsia 2001; 42: 796-803.

  10. García Pedroza F. La epidemiología de la neurocisticercosis en México. En: San Esteban JE (Ed.), Fisser A, González AA. Neurocisticercosis en la infancia. México, D.F.: Porrúa; 1997, p. 19-38.

  11. Secretaría de Salud. Causas de mortalidad en México en 1997. Dir. Gral. Epidemiología, SSA; 1999.

  12. Secretaría de Salud. Causas de morbilidad en México en 1999. Dir. Gral. Epidemiología, SSA; 2000.

  13. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 61: 433-43.

  14. Bell GS, Sander JW. The epidemiology of epilepsy: the size of the problem. Seizure 2001; 10: 306-14.

  15. García Pedroza F. La epilepsia como problema de salud pública. En: Feria Velasco A (Ed.), et al. Epilepsia: aspectos neurobiológicos, médicos y sociales. México, D. F.: Editores INNN; 1997, p. 402-26.

  16. Plascencia M, Shorvon SD, Paredes V, et al. Epileptic seizures in an Andean region of Ecuador: incidence and prevalence and regional variation. Brain 1992; 115: 771-82.

  17. Secretaría de Salud. Actualidades en Epilepsia. México: Ed. Programa Prioritario de Epilepsia: 2003, p. 7.

  18. Shackleton DP, Westendorp RG, Kasteleijn-Nolst Trenite DG, et al. Survival of patients with epilepsy: an estimate of the mortality risk. Epilepsia 2002; 43: 445-50.

  19. Morgan CL, Kerr MP. Epilepsy and mortality: a record linkage study in a U.K. population. Epilepsia 2002; 43: 1251-5.

  20. Arroyo S, Brodie MJ, Avanzini G, Baumgartner C, Chiron C, Dulac O, French JA, Serratosa JM. Is refractory epilepsy preventable? Epilepsia 2002; 43(4): 437-44.

  21. Secretaría de Salud. Sistema Nacional de Vigilancia Epidemiológica. NOM-017-1994-1999). SSA; 1999.

  22. Schant PM, Moore AC, Muñoz JL, et al. Neurocistycercosis in an orthodox Jewwish community in New York City. New Eng J Med 1992; 327: 692-5.

  23. Greeberg RS, Flanders WD, Eley JW, Daniels SR, Boring JR. Estudios de cohorte. En: Epidemiología clínica. Manual Moderno; 2002, Cap. 8: 123-53.

  24. Ídem (7). Estudios de cohorte. 11: 193-222.

  25. Lilienfeed AM, Lilienfeed DE. Observational studies. In: Foundations of epidemiology. Oxford University Press; 1980. Caps. 8-9: 191-255.

  26. Klinbaum DG, Kupper LL, Morgenstern H. Typology of observational study designs. In: Epidemiology research. NY: Van NR; 1982, 5: 62-95.

  27. Fletcher RH, Fletcher SW, Wagner EH. Risk. In: Waud W (Ed.). Clinical epidemiology. 2nd Ed.; 1988, 5: 91-105.

  28. Schleesslman JJ. Case-control studies. Oxford University Press; 1982, p. 1-354.

  29. Guerrero RV, González CL, Medina EL. Estudios de casos y controles o retrospectivos. En: Epidemiología 1981, Caps. 8-9: 101-21.

  30. Nicoletti A, Bartoloni A, Reggio A, Bartalesi F, Roselli M, Sofia V, Rosado Chávez J, Gamboa Barahona H, Paradisi F, Cancrini G, Tsang VC, Hall AJ. Epilepsy, cysticercosis and toxocariasis: a population-based case-control study in rural Bolivia. Neurology 2002; 58: 1256-61

  31. Berkovic SF, Scheffer IE. Genetics of the epilepsies. Epilepsia 2001; 42 (Suppl 5): 16-23.

  32. Anderson E, Berkovic S, Dulac O, et al. ILAE genetics commission conference report: molecular analysis of complex genetic epilepsies. Epilepsia 2002; 43: 1262-7.

  33. Ídem 16. Estudios diagnósticos. Cap. 6: 81-4.

  34. Mausner JS, Bahn AK. Examen en masa para detección de enfermedades y mantenimiento de la salud. En: Epidemiología 1977, Cap. 11: 223-42.

  35. Lancman ME, Benbadis S, Geller E, Morris HH. Sensitivity and specificity of asymmetric recall on WADA test to predict outcome after temporal lobotomy. Neurology 1998; 5: 455-9.

  36. Friedman LM, Furberg CD, De Mets DL. Fundamentals of clinical trials. In: Fundamentals of clinical trials. John Wright PSG Inc.; 1981, p. 1-225.

  37. Ídem 22. Estudios clínicos controlados. P. 124-34.

  38. Ídem 16. Estudios clínicos. P. 97-106.

  39. Ídem 20. Treament. P 129-56.

  40. Idem 18. Clinical trials. P. 256-71.

  41. Spiegel MR. Números aleatorios. En: Teoría y Problemas de Estadística. McGraw-Hill; 1970, p. 349.

  42. Christensen J, Andreasen F, Poulsen JH, Dam M. Randomized controlled trial of topiramate in refractory focal epilepsy. Neurology 2003; 61: 1210-8.

  43. Rafnsson V, Olafsson E, Hauser WA, et al. Cause-specific mortality in adults with unprovoked seizures: a population-based incidence cohort study. Neuroepidemiology 2001; 20: 232-6.

  44. Camfield CS, Camfield PR, Veugelers PJ. Death in children with epilepsy: a population-based study. Lancet 2002; 359: 1891-5.

  45. Nilsson L, Ahlbom A, Farahmand BY, et al. Risk factors for suicide in epilepsy: a case-control study. Epilepsia 2002; 43: 644-51.

  46. ILAE Commission of Epidemiology and Prognosis. The epidemiology of the Epilepsies: future directions. Epilepsia 1997; 38: 614-8.

  47. McDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48: 833-41.




2020     |     www.medigraphic.com